We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




European Network for Muscle Pathology

By Biotechdaily staff writers
Posted on 21 Mar 2005
A European network called Myores brings together 37 research groups in seven countries who will work toward the understanding of muscle development, function, and repair in order to develop therapies for various muscle pathologies.

Myores will bring together resources to tackle problems in a field that causes considerable suffering. More...
In Europe, more than 300,000 people are affected by various muscular dystrophies, while muscular degeneration is one of the most incapacitating features of aging. Network resources will pool European expertise and share nine high-technology platforms. The network will receive around U.S.$16 million in funding as part of the European Commission's 6th Framework Program for Research and Technical Development.

Three platforms will focus on gene attenuation using interfering RNA (iRNA), Drosophila transgenesis, and in vivo electroporation. Other platforms will focus on proteomics and micro-chips, molecular modeling, and molecular imaging. Data resulting from work on these platforms will be assembled in a common database, Myobase, to facilitate and accelerate access to results for all the network members. The results will help scientists to gain a better understanding of the molecular mechanisms involved in human repairing systems.

The French National Institute for Health and Medical Research (Inserm, Paris, France) will be in charge of the scientific coordination of Myores. Network partners include the University of Sheffield (UK), Clinical University, Freiburg (Germany), Institute Pasteur (France), School of Medicine, Pauda (Italy), Max Planck Institute (Germany), Hebrew University (Israel), Imperial College (London), and many others.





Related Links:
Inserm

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.